NYSE ACT:
at
HOME ABOUT WC PRODUCTS RESEARCH CAREERS INVESTOR RELATIONS SELECT ONE OF OUR PRODUCTS

Company News


Learn More About Our Products



About Actavis + Warner Chilcott   On October 1, 2013, Actavis (NYSE: ACT) announced the acquisition of Warner Chilcott plc, creating an $11 billion leading specialty pharmaceutical company with over $3 billion in pro forma sales. The combination capitalizes on the complementary specialty pharmaceuticals strengths and market positions of the two organizations, building a leader in Women’s Health and Urology, as well as a company with important positions in Gastroenterology and Dermatology. For more information, visit www.Actavis.com.

Warner Chilcott France revendique dans ses pratiques un respect des principes éthiques et veille à être exemplaire dans la mise en œuvre de ces engagements.


Contact Us        Grants        Terms of Use Agreement        Privacy Policy        Vendor Terms        Trademark Policy        Login